We validated the DNAJB1-PRKACA fusion protein as a source of immunogenic HLA class I and HLA class II-binding antigens inducing both CD8+ and CD4+ T cell responses, which is required for effective anti-cancer immunity44,45. This evidence concerns the gene CD8A and cancer.